{"id":391407,"date":"2015-05-11T00:00:00","date_gmt":"2015-05-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0615-biopharma-rheumatoid-arthritis-decision-base-us-2015\/"},"modified":"2026-04-15T10:00:57","modified_gmt":"2026-04-15T10:00:57","slug":"dbasim0615-biopharma-rheumatoid-arthritis-decision-base-us-2015","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbasim0615-biopharma-rheumatoid-arthritis-decision-base-us-2015\/","title":{"rendered":"Rheumatoid Arthritis | Decision Base | US | 2015"},"content":{"rendered":"<p><em>Which Efficacy and Safety Achievements Will Differentiate Emerging Therapies in a Crowded Market Filled with Efficacious Drugs?<\/em><\/p>\n<p>Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral kinase inhibitor (tofacitinib [Pfizer\/Takeda Pharmaceutical\u2019s Xeljanz]). Given rheumatologists\u2019 long-standing familiarity with the safety and efficacy profiles of the tumor necrosis factor-alpha (TNF-\u03b1) inhibitors and, increasingly, of non-TNF-\u03b1 agents abatacept (Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s Orencia), rituximab (Biogen Idec\/Roche\/Chugai\/Zenyaku Kogyo\u2019s Rituxan, Roche\u2019s MabThera), and tocilizumab (Roche\/Chugai\u2019s RoActemra\/Actemra), new agents face challenges in gaining uptake. To help drug developers negotiate the formidable barriers to uptake in this market, this report identifies attributes with the greatest power to influence rheumatologists\u2019 prescribing decisions and the gaps in efficacy and safety of select current and emerging therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391407","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391407\/revisions"}],"predecessor-version":[{"id":394530,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391407\/revisions\/394530"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}